
Luxury skincare expansion: L'Oreal acquires majority stake in Medik8; announces 1 billion Euro deal
Cosmetics maker L'Oreal agreed to acquire a majority stake in British skincare brand Medik8, in a strategic move to strengthen its presence in the booming skincare market.
The French beauty giant announced the deal on Monday, though financial terms were not disclosed.
The transaction, which sees UK-based private equity firm Inflexion selling its majority holding, reportedly values Medik8 at around 1 billion Euro, according to a source familiar with the matter. Inflexion will retain a minority share, while L'Oreal has secured the option to eventually buy out all remaining shareholders, Reuters reported.
'We are delighted to welcome Medik8 to the L'Oréal family. As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio,' Cyril Chaupuy, president of L'oreal Luxe said.
'This acquisition further strengthens L'Oreal's luxe portfolio, adding a premium science-backed skincare brand with a proven track record of success, with strong potential for global growth,' the company said in a statement.
L'Oreal will begin consolidating Medik8's sales once the transaction officially closes. The acquisition is expected to be finalised in the coming months, pending regulatory approvals and standard closing conditions.
Simon Coble, CEO of Medik8 also expressed excitement on the brand's behalf.
'I am delighted to be joining forces with a company which shares our vision for the brand's future growth and whose core values align with our deep commitment to science, innovation and above all, results without compromise. I look forward to the next stage in Medik8's journey, as we work together to bring our innovative products to a wider audience.'
Founded in the UK, Medik8 has built a loyal customer base with its vitamin A-focused anti-ageing creams and serums. The brand is seen as a natural fit for L'Oreal's luxury division, which includes skincare and fragrance names such as Lancome, Aesop, and Miu Miu.
Last year, sales in L'Oreal's luxe segment grew by just 2.7%, its weakest performance across divisions, as inflation pushed consumers toward more affordable alternatives. However, the unit scrored better than rival LVMH's beauty arm.
Stay informed with the latest
business
news, updates on
bank holidays
and
public holidays
.
AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)

Business Standard
27 minutes ago
- Business Standard
Free run to bumpy ride: Ola Electric faces challenges on road to future
Unlike services, Ola's foray into product manufacturing comes with a different set of expectations Peerzada Abrar Bengaluru Listen to This Article In 2021, Bhavish Aggarwal stood on a dusty plot in the Krishnagiri district of Tamil Nadu, and promised to build the world's largest electric two-wheeler factory. Within eight months—and despite the challenges posed by the Covid19 pandemic—that vision became the Ola Futurefactory. The facility, staffed entirely by women and run mainly by robots, aims to have an annual production capacity of 10 million units in future. Backed by SoftBank, Ola Electric quickly became the market leader. Soon after, it made a blockbuster market debut in 2024, its IPO valuing the firm at $4.8 billion. Cut to 2025. Bengaluru-based Ola Electric's


Time of India
an hour ago
- Time of India
HC nod for Turkish co to take inventory at city airport
Chennai: Madras high court has allowed Turkey-based company, Celebi Ground Services, to enter the Chennai airport premises for taking an inventory after getting prior approval from airport authorities. Justice Abdul Quddhose issued an interim order to this effect on Monday, on a petition filed by Celebi Ground Services Chennai Pvt Ltd, challenging cancellation of concession agreement by Airport Authority of India (AAI) following the cancellation of its security clearance by BCAS under ministry of civil aviation on May 26. When the plea came up for hearing, senior advocate P S Raman, representing the company, submitted that it had invested huge amounts of money in its equipment and software and that the AAI was attempting to appoint third parties who would exploit these instruments. The sudden cancellation of the agreement caused a huge financial loss to the company, and it was done due to vendetta, he added. He wanted the court to pass an interim injunction restraining the AAI from creating any third-party rights. Solicitor-general Tushar Mehta, representing AAI, submitted that it was necessary to appoint a third party for smooth functioning of the airport. To this, Raman informed the court that relief was granted by Bombay high court in a similar petition. Opposing the argument, Mehta submitted that the facts of the present case were different from those of the one pending before the Bombay HC. Recording the submissions, the court directed AAI to file counter to the petitions and adjourned hearing to July 7.


The Hindu
an hour ago
- The Hindu
Advent to invest $175 million in Felix Pharma to acquire minority stake
Advent, a private equity investor, has announced that funds managed by it have signed a definitive agreement to invest $175 million via primary and secondary capital for a significant minority stake in Dublin, Ireland-based Felix Pharmaceuticals Pvt. Ltd. (Felix), a global Gx animal pharma player. Felix Pharma is one of the developers and manufacturer of off-patent medicines for companion animals. Felix develops, manufactures and supplies to distributors and other branded Gx players for private labelling, particularly in the U.S. Shweta Jalan, Managing Partner, Advent, said, 'Healthcare has been a long-standing focus for us, and strong parallels we see between success in human Gx globally and emerging opportunity in animal health Gx. Felix is well positioned to lead this space with its strong leadership, broad portfolio, and robust R&D and commercial capabilities.' 'Its rapid growth and high customer satisfaction make it a differentiated platform, and we are excited to support Neeraj and the Felix team in scaling it into a global franchise,' she added, Founded in 2015 by Neeraj Agrawal, a McKinsey alum, Sir Jonathan Symonds, Chair of GSK and with 30 years of experience in global pharmaceuticals, and Dr. Shumeet Banerji, ex-CEO of Booz-Allen, Felix said it has pursued strategic growth through a disciplined approach, While the company achieved its first U.S. FDA approval in 2020, it has quickly scaled to a 14 commercialised product portfolio and has several others in advanced stages of pipeline. It has a USFDA-approved oral solid facility dedicated to animal health products and an injectable facility that is expected to be ready by Q3 2025. Neeraj Agrawal, Co-Founder, Felix Pharma, said, 'As we scale in a fast-evolving market, we were looking for a partner who brings not just capital, but also deep operating expertise and the right mindset and networks to help us grow faster and stronger. Advent's strong track record in healthcare and pharma, and their close involvement in building strong businesses, gives us great confidence.'